Full-Time

Microbiologist

Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

51-200 employees

Develops, acquires, and markets generic drugs

Compensation Overview

$80k - $85k/yr

+ Bonus

Sacramento, CA, USA

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Microbiology

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor’s degree in microbiology, Biology, or related field required
  • Minimum of 3 years of experience in a microbiology laboratory required
  • Experience with compendia testing: United States Pharmacopeia, and regulatory requirements (Food and Drug Administration and cGMP) preferred
Responsibilities
  • Conducts microbiological testing of primary packaging materials, raw materials, in process sample, finished products, and environmental samples using various techniques, including microbial enumeration, identification, and antimicrobial effectiveness testing
  • Develops and validates microbiological test methods in accordance with compendial and regulatory requirements
  • Maintains accurate and detailed records of all microbiological testing and analysis performed
  • Prepares and reviews reports, protocols, and SOPs related to microbiological activities
  • Ensures compliance with regulatory standards, current Good Manufacturing Practices (cGMP) requirements, and company policies and procedures
  • Participate in internal and external audits as needed
  • Microbiology-related projects, including method transfers, validations, and investigations
  • Collaborates with cross-functional teams to achieve project objectives and timelines
  • Provides training and mentorship to microbiology staff
  • Shares knowledge and expertise to promote continuous learning and development within the microbiology team
  • Identifies opportunities for process improvements and optimization within the microbiology laboratory
  • Implements best practices and innovative solutions to enhance efficiency and effectiveness
  • Performs a variety of Microbiology testing to assess the strength, identity, and purity of test samples and/or materials
  • Performs other duties as assigned
Desired Qualifications
  • Master’s degree in microbiology or a related field preferred
  • Previous experience in a pharmaceutical or compounding environment preferred
  • Experience with compendia testing (United States Pharmacopeia) and regulatory requirements (FDA and cGMP) preferred
  • Experience with microbiological method development and method validation procedures like Sterility Testing, Endotoxin Testing, Disinfectant Efficacy Study, Water Testing, Method Validation, Environment Monitoring, Microbial Limit Testing, PET, and microbiological hold time validation, container closure integrity.
Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

View

Nivagen Pharmaceuticals develops, acquires, and sells generic prescription drugs and OTC products for the North American market. It leverages global partnerships with FDA-approved manufacturing facilities to deliver high-quality, affordable products and collaborates with the world’s best CROs and CRAMs to develop and manufacture niche generics. The company supports small FDA-qualified manufacturers entering the U.S. market and differentiates itself through its ability to launch new generic products and its strong sales and marketing team, rather than relying on a single manufacturing or development approach. Revenue comes from product development, co-development, acquisitions, in-licensing, and providing sales and marketing services. Nivagen aims to grow its portfolio by forging CRO/CRAM partnerships, acquiring existing products, and expanding its product lineup to capture a larger share of the evolving generic and OTC market in North America.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$26M

Headquarters

Sacramento, California

Founded

2009

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PAI Pharma's January 6, 2026 acquisition brings Olympus-backed capital and distribution.
  • Owning the Sacramento site after February 2026 strengthens expansion and regulatory control.
  • Shortage-sensitive injectable demand supports faster commercialization for Nivagen's RTU pipeline.

What critics are saying

  • Nivagen's zinc oxide Class II recall, started October 31, 2025, remains ongoing.
  • California recalled atorvastatin tablets in September 2024 for a carbamazepine mix-up.
  • Repeated cGMP failures or sterile contamination would trigger FDA shutdowns and destroy hospital trust.

What makes Nivagen Pharmaceuticals unique

  • Sacramento's 100,000-square-foot sterile facility makes Nivagen unusually domestic for injectables.
  • Nivagen built over 20 ready-to-use sterile injectables before PAI Pharma's January 2026 acquisition.
  • Its 503B compounding and CDMO services target shortage-driven hospital demand directly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

401 (k) savings plan

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-7%
PE Hub
Jan 6th, 2026
Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals

Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals. Headquartered in Greenville, South Carolina, PAI is a developer, manufacturer and marketer of oral liquid medicines. * Nivagen operates an aseptic manufacturing facility in Sacramento, California, designed to support the production of IV bags, vials, prefilled syringes, and cartridges * Nivagen was founded in 2009 PAI Pharma, which is backed by Olympus Partners, has acquired Nivagen Pharmaceuticals, Inc, a Sacramento, California-based pharmaceutical company. No financial terms were disclosed. Gain instant access to our expert editorial analysis and in-depth insight. Already have an account? Sign in.

Benzinga
Jan 6th, 2026
PAI Pharma acquires Nivagen to expand US sterile injectable manufacturing amid persistent drug shortages

PAI Pharma, a portfolio company of Olympus Partners, has acquired Nivagen Pharmaceuticals, a California-based pharmaceutical company specialising in ready-to-use sterile injectables. The deal expands PAI's domestic manufacturing capabilities and addresses persistent drug shortages in the US healthcare system. Nivagen operates a state-of-the-art aseptic manufacturing facility in Sacramento, producing IV bags, vials, prefilled syringes and cartridges. The company brings over 20 injectable products to complement PAI's existing sterile portfolio of approximately 10 products in development and four on the market. The acquisition aligns with growing efforts to reshore pharmaceutical production and reduce reliance on foreign supply chains. PAI Pharma was advised by Bourne Partners, Kirkland & Ellis and KPMG, whilst Olympus Partners provided backing for the transaction.

Private Equity Info
Aug 22nd, 2022
Corbel Capital Partners invests into Nivagen Pharmaceuticals, Inc.

Corbel Capital Partners invested in Nivagen Pharmaceuticals (Sacramento, CA, US), a specialty pharmaceuticals business that develops and sells generic and branded prescription drugs.